Abstract Proliferation of bovine aortic smooth muscle cells (SMCs) induced by thrombin, basic fibroblast growth factor, or serum is inhibited by anionic, nonsulfated aromatic compounds that mimic many of the effects of heparin. Among these compounds are aurintricarboxylic acid (ATA) and a newly synthesized polymer of 4-hydroxyphenoxy acetic acid (compound RG-13577). Iodinated-or 14 C-labeled compound RG-13577 binds to cultured SMCs in a highly specific and saturable manner. Scatchard analysis of the binding data revealed the presence of an estimated lxlO 7 binding sites per cell with an apparent dissociation constant of 3xlO~6 mol/L. Binding of radiolabeled RG-13577 was efficiently competed for by related aromatic anionic compounds and by apolipoprotein E, but not by heparin, heparan sulfate, suramin, or various purified growth factors and extracellular matrix proteins.
T he pathogenesis of atherosclerosis involves abnormal migration and proliferation of smooth muscle cells (SMCs) that become infiltrated with macrophages and embedded in extracellular matrix (ECM). 1 -2 Under physiological conditions, the majority of arterial SMCs remain in the G o phase, and cell growth is controlled by a balance between endogenous gTOwth-promoting factors and proliferation-inhibiting molecules (eg, heparan sulfate proteoglycans). Following endothelial cell perturbation due to the activation of atherogenic risk factors, platelets and non-plateletderived growth factors and cytokines are released and stimulate monocyte and SMC migration as well as SMC proliferation.
1 ' 2 Among these growth factors are platelet-derived growth factor (PDGF), 3 basic fibroblast growth factor (bFGF), 4 and interleukin-1 (IL-1). 5 Macrophages and platelets also release enzymes (eg, elastase, collagenase, and heparanase) that digest various constituents of the ECM and may release bFGF and other growth factors (ie, transforming growth factor-R I-RG-13577 revealed a single species of high M, (»=280 kD) cell surface receptors detected in the absence but not the presence of excess unlabeled compound RG-13577. Binding was susceptible to downregulation and restoration of receptor levels in a manner similar to that of hormone and growth factor receptors. We suggest that the antiproliferative activity of compound RG-13577 and related compounds is initiated by binding to specific growth-inhibiting cell surface receptors. Heparin-mimicking compounds may be applied to inhibit SMC proliferation associated with atherosclerosis and restenosis. (Arterioscler Thromb. 1994; 14:1992 -1999 Key Words • heparin mimetics • antiproliferative activity • aurintricarboxylic acid • heparan sulfate • vascular smooth muscle cells ) that are stored in the basement membrane and ECM. 6 A potent SMC growth-promoting activity is also exerted by thrombin, which, under certain conditions, may be present within the vessel wall. 78 Molecules that interfere with the growth-promoting activity of these growth factors may attenuate progression of the atherogenic process. Among these interfering molecules are species of heparin 9 and heparan sulfate 10 that inhibit proliferation of vascular SMCs both in vitro and in vivo. Heparan sulfate may therefore function as an endogenous inhibitor of arterial SMC growth. 11 ' 12 The regulation of cell proliferation by heparan sulfate may involve receptor-mediated endocytosis of heparan sulfate 13 and/or interaction with heparin-binding growth factors 14 and growth factor receptors. 15 Recent studies indicate that both the antiproliferative activity of heparan sulfate and its specific interaction with bFGF reside in sulfate-rich domains enriched with 2-0-sulfated uronic acid residues. 1016 In a search for synthetic and better-defined heparin-like molecules, we have recently identified a series of polyanionic polymers composed of repeating phenol-based monomers (eg, polyhydroxyphenoxy acetic acid) that mimic many of the effects of heparin. 17 These nonsulfated anionic compounds, among which are commercially available synthetic polymers (ie, aurintricarboxylic acid [ATA]), phenotype of bFGF-transfected cells in terms of their proliferation rate, morphological appearance, adhesive properties, and availability of bFGF receptors. 17 We now present evidence that these newly identified synthetic compounds bind to specific receptor(s) on the surface of arterial SMCs and inhibit the proliferation of vascular SMCs induced by thrombin, bFGF, and serum.
Methods Materials
Recombinant bFGF was kindly provided by Dr Peter Bohlen (Lederle Laboratories). Recombinant human apolipoprotein (apo) E3 was kindly provided by Dr Tikva Vogel (Bio Technology General Ltd). Dulbecco's modified Eagle's medium (DMEM); fetal calf serum (FCS); penicillin; streptomycin; and saline containing 0.05% trypsin, 0.01 mol/L sodium phosphate (pH 7.4), and 0.02% EDTA (STV) were obtained from Biological Industries. Tissue-culture dishes were obtained from Falcon Labware Division, Becton Dickinson. [ 125 I]NaI was obtained from Amersham. Compound RG-13577 (a polymer of 4-hydroxyphenoxyacetic acid and formaldehyde ammonium salt; M r ~58O0) (Fig 1) , 14 C-labeled RG-13577 (25.6 jtCi/mg), and related compounds were synthesized and kindly provided by Rhone-Poulenc-Rorer Co. 19 [
3 H]Methylthymidine (5000 mCi/mmol) was obtained from New England Nuclear. ATA, methylene blue, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and all other chemicals were of reagent grade and were purchased from Sigma Chemical Co.
Human Thrombin Preparations
Highly purified human thrombin (3975 U/mg) was prepared from fraction III paste, evaluated for purity, and characterized by Dr J.W. Fenton II (Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany). 7 The thrombin preparation used in the experiments consisted of 98% «-, 1.8% p-, and 0.7% -y-thrombin and was titrated to >85% of the active enzyme with p-nitrophenyl-p-guanidinobenzoate (NPGB).
Cells
SMCs were isolated from bovine or rat aortic media. 9 Briefly, the abdominal segment of the aorta was removed and the fascia cleaned away under a dissecting microscope. The aorta was cut longitudinally, and small pieces of the media were carefully stripped from the vessel wall. Two or three such strips with average dimensions of 2x2 mm were placed in 60-mm tissue-culture dishes that contained DMEM (4.5 g glucose per liter) supplemented with 10% FCS, 100 U/mL penicillin, and 100 iig/mL streptomycin. Within 7 to 14 days, large patches of multilayered cells had migrated from the explants. Approximately 1 week later, the cells were subcultured into 100-mm tissue-culture plates (4 to 6X10 3 cells per plate). The cultures (passages 3 through 8) exhibited morphological characteristics typical of vascular SMCs, and the cells were specifically stained with monoclonal antibodies that selectively recognize a muscle form of actin . This antibody does not recognize endothelial cells or fibroblasts. 20 Foreskin fibroblasts (passages 3 through 9) were maintained in DMEM (4.5 g glucose/L) supplemented with 10% FCS and antibiotics, as described above. Clonal populations of bovine aortic endothelial cells were established and cultured. 21 
Iodination and Binding of bFGF
Recombinant bFGF was iodinated using chloramine T. 17 -22 Briefly, bFGF (5 jig) was added to 60 /iL 0.2 mol/L sodium phosphate, pH 7.2, containing 1 mCi [ 125 I]NaI. Chloramine T (10 mL of 1 mg/mL) was added for 45 seconds at room temperature, and the reaction was stopped by the addition of 50 fiL 0.05% sodium metabisulfite and 50 /xL of 10 mmol/L KI. The reaction mixture was then applied onto a small (0.3-mL) heparin-Sepharose column equilibrated with 0.6 mol/L NaCl in 20 mmol/L phosphate buffer, pH 7.2. The column was washed with the same buffer, and the 125 I-bFGF was eluted with 1.5 mL phosphate buffer containing 2 mol/L NaCl, 0.3% CHAPS, and 0.2% gelatin. The specific activity was 1.2 to 1.7X10 3 cpm/ng bFGF, and the labeled preparation was kept for up to 3 weeks at 4°C. Binding of 12! I-bFGF to low-and high-affinity receptor sites on vascular SMCs was performed.
14 ' 17 Nonspecific binding determined in the presence of 10 /ig/mL heparin or a 200-fold excess of unlabeled bFGF did not exceed 15% of the total lowand high-affinity-bound bFGF.
Iodination of RG-13577
Compound RG-13577 was iodinated with chloramine T. Briefly, RG-13577 (50 ^g) was added to 60 /*L 0.2 mol/L sodium phosphate, pH 7.2, and 40 mL water containing 1 mCi [ 125 I]NaI. Chloramine T (15 /iL of 10 mg/mL) was added for 45 seconds at room temperature, and the reaction was stopped by the addition of 50 fiL 0.1% sodium metabisulfite and 50 yL 0.2% KI. Free iodine was removed by extensive dialysis against water at 4°C. Specific activity was 1.5 to 2x10* cpm/ng RG-13577, and the labeled preparation was kept for up to 5 weeks at 4°C. "C-RG-13577 (56 cpm/ng) was synthesized by RhonePoulenc-Rorer in a manner identical to that used for the native, unlabeled molecule. 19 No differences in receptor binding and biological activity could be detected between the 14 C-and 125 I-labeled RG-13577. Moreover, native and radioactively labeled RG-13577 exhibited comparable antiproliferative activity.
Binding of I25 I-RG-13577 to SMCs
Cells were grown to confluency in 16-mm culture wells (4 to 5X10 5 cells/well). Confluent cultures were washed once with phosphate-buffered saline (PBS), and incubated at 4°C in DMEM containing 0.2% bovine serum albumin (BSA) and 20 mmol/L HEPES.
I25 I-RG-13577 was then added at the indicated concentrations, and the cultures were incubated at 4°C for 2 hours, washed three times with DMEM containing 2 mg/mL BSA, and dissolved in 1 mol/L NaOH. Radioactivity was determined by counting in a Beckman model 5500 gamma counter. Nonspecific binding, determined in the presence of a 1000-fold excess of unlabeled RG-13577, did not exceed 20% of the total binding. the absence or presence of excess (1 mg/mL) unlabeled compound RG-13577. The cells were washed twice with icecold PBS containing 0.2% BSA, 0.01% MgCl 2 , and 0.01% CaCl 2 (all vol/vol). Cell-bound 123 I-RG-13577 was cross-linked by incubation (30 minutes, 24°C) with 15 mmol/L EDC in PBS. 717 To quench the excess free EDC, the cells were incubated (1 minute, 24°C) in a solution containing 10 mmol/L Tris-HCl, pH 7.5, and 150 mmol/L glycine and were then washed with ice-cold PBS. For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of crosslinked proteins, the cells were scraped, centrifuged (10 minutes, 4°C), and resuspended in 80 fiL lysis buffer (50 mmol/L Tris-HCl, pH 8.0; 150 mmol/L NaCl; 0.5 mmol/L MgCl 2 ; 0.5% Nonidet P-40; and 1 mmol/L phenylmethylsulfonyl fluoride [PMSF]). After centrifugation (15 000g, 1 minute), the supernatant fraction was mixed with SDS-PAGE sample buffer, boiled, and analyzed by SDS-PAGE on a 3% to 10% gradient polyacrylamide gel. 717 For autoradiography, the gels were fixed, dried, and exposed to Kodak X-Omat film at -70°C.
Cell Proliferation [ 3 H]Thymidine Incorporation
SMCs were plated (4x10* cells per 16-mm well) in DMEM supplemented with 10% FCS. Twenty-four hours after seeding, the medium was replaced with medium containing 0.2% FCS, and 48 hours later the cells were exposed to growth stimulants and [ 
Growth Rate
SMCs (1.5x10* cells/well) were seeded into 24-well culture plates and exposed to growth stimulants as described above. One to 6 days after seeding, the cells were fixed with 2.5% formaldehyde in PBS. The plates were immersed in a bath of 0.1 mol/L borate buffer (pH 8.5), stained (1 hour, 24°C) with methylene blue (1% in 0.1 mol/L borate buffer, pH 8.5), and washed four times in water. This procedure removed practically all non-cell-bound dye. Specific cell-incorporated methylene blue was dissolved with 0.5 mL of 0.1N HC1 (1 hour, 25°C) and determined by measuring the absorbance at 620 nm. 7 Cell number as determined by cell counting correlated with that as determined by spectrophotometric absorbance. 7 -23 The initial cell plating density was chosen to ensure a linear relation between cell number and absorbance at the end of the experiment. In each experiment, three wells were fixed before adding the test compound to determine the average initial absorbance. This value was used to calculate doubling times of control and drug-treated cells by using the following equation:
where DT is the doubling time in hours, OD, is the optical density of a test well at the end of the experiment, OD C is the optical density of a control well at the beginning of the experiment, and h is the duration of incubation in hours. The growth rate was calculated by dividing the doubling time of drug-treated cells by that of control cells.
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Cell Number
Cells were seeded at a density of 5X10 3 cells/well of a 24-well plate. At various times after seeding, the cells were dissociated with STV and counted in a Coulter counter (Coulter Electronics Ltd). 17 Each of the aforementioned cell proliferation and receptorbinding experiments was performed at least three times, and the variation between different experiments did not exceed ±20%.
Results
Inhibition of SMC Proliferation Induced by Thrombin, bFGF, or Serum
Migration and proliferation of vascular SMCs in response to growth-promoting factors, such as bFGF, PDGF, and thrombin, play an important role in the pathogenesis of atherosclerosis. 1 -2 The "heparin-mimicking" compound RG-13577 was analyzed for its ability to inhibit thymidine incorporation induced by these growth factors in SMCs. For this purpose, SMCs were seeded at a low density (3 to 4x10* cells per 16-mm well), arrested at the Go/G] phase by serum deprivation (0.2% FCS, 48 hours), and incubated (48 hours, 37°C) with various concentrations (0.05 to 5 Mg/mL) of RG-13577 in the absence or presence of thrombin, bFGF, or 10% FCS. Under these experimental conditions, thymidine incorporation was increased by 6.5-, 6-, and 13-fold, respectively, in SMCs exposed to 0.1 j£mol/L thrombin, 1 nmol/L bFGF, and 10% FCS. Thymidine incorporation induced by 0.1 /imol/L thrombin was inhibited by 80% in the presence of 0.25 /xg/mL compound RG-13577 (Fig  2A) . A 50% reduction in thymidine incorporation induced by 1 nmol/L bFGF or 10% FCS was observed in the presence of 1 to 2 /xg/mL RG-13577. Compound RG-13577 inhibited the proliferation of serum-stimulated rat and bovine aortic SMCs to a similar extent. Proliferation of bovine aortic endothelial cells in response to bFGF was inhibited by RG-13577, albeit to a somewhat lower degree, compared with bovine aortic SMCs (50% inhibition of [ 3 H]thymidine incorporation at 4 /xg/mL RG-13577). Similar results were obtained with a series of related anionic aromatic compounds whose structure and preparation have been described in a recent study 19 (not shown). The rate of thrombin-induced cell proliferation, as evaluated by the methylene blue assay, was inhibited by 70% in the presence of 0.5 mg/mL RG-13577 (Fig 2B) . The related commercially available compound ATA was a somewhat less efficient inhibitor of SMC proliferation, yielding a 50% to 60% reduction in growth rate at 5 ^.g/mL. SMC proliferation induced by thrombin was not inhibited by 5 /xg/mL suramin (Fig 2B) . SMCs treated with ATA or compound RG-13577 remained viable, as indicated by the exclusion of trypan blue by more than 90% of the cells and the restoration of thymidine incorporation by cells that were treated for 48 hours with 1 /xg/mL ATA or RG-13577, washed free of the inhibitor, and reexposed to thrombin (not shown). Compound RG-13577 also inhibited the proliferation of vascular SMCs induced by bFGF or FCS. Almost complete inhibition of cell proliferation was obtained in the presence of 2.5 jig/mL RG-13577, with only a small effect at 0.5 Mg/mL (Fig 2C) , similar to the effect of compound RG-13577 on pH]thymidine incorporation induced by these mitogens (Fig 2A) . Compound RG-13577 (2.5 /ig/mL) also completely inhibited the synergistic stimulation of SMC proliferation induced by both bFGF and thrombin.
Effect of Compound RG-13577 on Binding of bFGF to Cell Surface Receptors
Cell interaction with bFGF and the resulting proliferative response involve binding to low-and high-affinity cell surface receptor sites. sites on SMCs was inhibited by about 80% in the presence of 5 ^g/mL RG-13577, similar to the inhibition of SMC proliferation obtained by this compound (Fig 2) . Direct interaction between compound RG-13577 and bFGF was suggested by the ability of the former to release 12i I-bFGF that was first bound to the ECM or heparin-Sepharose. This result suggests that l23 I-bFGF binds to compound RG-13577 and that the complex can no longer bind to heparan sulfate on the SMC surface. Likewise, binding of 7 sites per cell. When SMCs were incubated for different times with 0.1 /xg/mL I25 I-RG-13577, increased binding was observed during the first 40 minutes, remaining at a similar level thereafter (Fig 4B) . Competition studies revealed that 25 /xg/mL RG-13577 decreased the specific binding of 0.1 /xg/mL 125 I-RG-13577 to 35% of total binding (Fig 4C) . A similar effect was obtained in the presence of excess ATA and a series of related anionic nonsulfated aromatic compounds 19 (not shown). Binding of 125 I-RG-13577 was also efficiently decreased in the presence of excess apoE (Fig 4C) . On the other hand, suramin failed to inhibit the binding of RG-13577 to SMCs, even at concentrations as high as 500 /xg/mL. Excess heparin had no effect on RG-13577 binding up to a concentration of 100 /xg/mL, yielding a 40% decrease in binding at 500 /xg/mL (Fig 4C) . Likewise, bFGF (50 /xg/mL), TGF-0 (30 /tg/mL), heparan sulfate (100 /xg/ mL), fibronectin (250 /xg/mL), or laminin (250 /xg/mL) failed to inhibit the binding of I25 I-RG-13577 to SMCs. Pretreatment of SMCs with glycosaminoglycan-degrading enzymes (ie, heparinase, chondroitinase ABC, or chondroitinase AC) or with tunicamycin had no effect on the ability of SMCs to bind compound RG-13577 (not shown). Similar results were obtained when 
Loss and Recovery of Cell Surface Receptors That Bind RG-13577
To further elucidate the properties of the RG-13577 receptor sites, vascular SMCs were tested for their ability to regulate the number of cell surface receptors following exposure to unlabeled RG-13577. For this purpose, confluent SMC cultures were preincubated (16 hours, 37°C) with increasing concentrations (10 to 200 /xg/mL) of RG-13577. The cells were then washed free of unbound material, incubated (3 hours, 3°C) with DMEM containing 2.5% FCS to allow membrane-bound RG-13577 to become internalized, and tested for their ability to rebind 14 C-labeled RG-13577. As shown in Fig 5A , preincubation of SMCs with 50 /xg/mL RG-13577 induced a 60% reduction in RG-13577 binding capacity. A similar result was observed following preincubation with 200 /xg/mL RG-13577 (Fig 5A) . In other experiments, cells that were first incubated with 200 xxg/mL RG-13577 to downregulate RG-13577 binding sites were washed, incubated for different times without RG-13577, and tested for their ability to rebind '"C-RG-13577. The results (Fig 5B) indicate that SMCs are capable of gaining their initial RG-13577 binding capacity after about 6 hours of incubation. These results suggest that the number of cell surface binding sites for RG-13577 can be modulated in a manner similar to that of membrane receptors for growth factors and hormones. In view of the relatively high concentrations of ligand that had to be applied in these experiments, the biological relevance of this finding is not clear. To elucidate whether ligandreceptor complexes can be internalized by the cells, we compared the amount of RG-13577 associated with SMCs at 4°C and 37°C. The results, summarized in Fig  5C, indicate a twofold increase in specific cell-associated RG-13577 at 37°C compared with that at 4°C, suggesting 12 
RG-13577, jig/ml
Time, h The cells were washed three times and incubated (3 hours, 37°C) in DMEM containing 2.5% FCS to permit internalization and degradation of the bound RG-13577. The cell monolayers were then washed four times, and their capacity to specifically rebind 14 C-flG-13577 (10 ng/mL) was determined under standard conditions (2 hours, 4°C). B, Recovery of RG-13577 binding capacity. SMC cultures were exposed (16 hours, 37°C) to 200 jtg/mL RG-13577 in DMEM containing 2.5% FCS. The cells were then washed three times and Incubated (3 hours, 37°C) in DMEM containing 2.5% FCS, followed by incubation (37°C) in DMEM containing 10% FCS for the indicated time intervals. Specific binding of 14 C-F1G-13577 (10 jtg/mL) was then measured as described above. C, Effect of temperature. Confluent SMCs were incubated (2 hours) at 4°C (A) or 37°C (•) with DMEM containing 0.2% bovine serum albumin, 20 mmol/L HEPES, pH 7.4, and increasing concentrations of M C-RG-13577. The cells were washed three times, and the amount of specifically bound RG-13577 was determined. The variation between triplicate determinations did not exceed ±20% of the mean.
that cell-bound RG-13577 molecules are internalized by the cells, albeit to a low extent.
Cross-linking of I2J I-RG-13577 Molecules to Cell Surface Receptors on SMCs
In an attempt to identify the specific cell surface receptor(s) for RG-13577 and determine its nature and molecular size, a cross-linking experiment was performed. For this purpose, SMCs cultured in a 10-cm dish were incubated (2 hours, 4°C) with 0.9 g 125 I-RG-13577 in the presence or absence of a 500-to 1000 -fold excess of unlabeled RG-13577. The cells were washed free of unbound molecules and subjected to cross-linking with 15 mmol/L EDC, and the cell extracts were analyzed by SDS-PAGE and autoradiography. A single major diffuse band with an apparent M, of =280 kD was visualized when the binding and cross-linking were performed in the absence but not in the presence of excess unlabeled RG-13577 (Fig 6) . The intensity of this high-molecular-weight cross-linked protein was slightly reduced when excess heparin (0.5 mg/mL) was added to the binding medium, but there was no effect in response to suramin. The apparent molecular weight of the cross-linked protein was similar under both reducing and nonreducing conditions. A similar receptor protein was identified in cross-linking experiments performed with bovine vascular endothelial cells and human skin fibroblasts (not shown).
Discussion
Heparin and heparan sulfate suppress the entry of SMCs into the S phase in response to some mitogens, but the mode of action remains unclear. 912 A recent study provides evidence that the antiproliferative activity of artery-derived heparan sulfate resides in its highly sulfated domains, which are enriched in hexuronate-2-sulfate residues, with a minimum length of four or five disaccharide units. 10 In the present report we demonstrate potent inhibition of vascular SMC proliferation by synthetic poryaromatic anionic compounds that mimic many of the effects of heparin.
17
- 19 A most potent inhibition of arterial SMC proliferation was exerted by compound RG-13577, a newly synthesized polymer of 4-hydroxyphenoxy acetic acid. 17 ' 19 Related polymeric compounds such as ATA were also effective, yielding a 50% inhibition of SMC proliferation at 0.5 to 5 tiglmL, depending on the specific compound and growth-pro-moting factor. Under the experimental conditions applied in the present study, both heparin and suramin at a concentration of 5 jig/mL failed to inhibit the proliferation of SMCs. Likewise, RG-13577 and related compounds were 10-and 100-fold more active than heparin and suramin, respectively, in reversing the transformed phenotype of bFGF-transfected 3T3 fibroblasts. 17 It is noteworthy that in other systems, such as blood coagulation, 19 inhibition of heparanase activity, release of ECMbound bFGF, or release of lipoprotein lipase from endothelial cells, heparin was twofold through 10-fold more active than compound RG-13577 (Ishai Michaeli et al, unpublished data, 1994) .
With respect to its detailed chemical structure, RG-13577 differs from heparin. While heparin contains sulfonate as the major anionic group, RG-13577 and ATA contain only carboxylic acid residues (Fig 1) . In addition, RG-13577 is composed of aromatic rings linked by an enzyme-resistant methylene group, whereas heparin has a biodegradable sugar backbone. RG-13577 and heparin each represent a family of polymers of repeating units. The estimated molecular weight of the active compound of RG-13577 is =>5800 19 ; the molecular weight of commercially available heparin is within the range of 5000 to 30 000. 27 Several possible mechanisms have been proposed for the antiproliferative activity of heparin. For example, for some cells and mitogens, growth inhibition may involve inactivation of the mitogen by heparin. 28 It should be noted that many transcription factors have heparin-binding basic amino acid sequences, suggesting that species of heparin and heparin-like molecules may under certain circumstances regulate gene activity at nuclear sites. 1112 It remains to be elucidated whether the "heparin-mimicking" compounds applied in the present study are internalized by the cells and whether this may then affect gene expression. Internalization was suggested by the increased amount of radioactivity associated with SMCs that were incubated with I25 I-RG-13577 at 37°C compared with that at 4°C and by a decreased binding capacity of cells that were first incubated (4 hours, 37°C) with unlabeled RG-13577 to elicit "downregulation" of the respective cell surface receptors.
Binding experiments performed with radioactively labeled RG-13577 revealed saturable binding to specific cell surface receptors. Binding was effectively competed by unlabeled RG-13577, ATA, and related "heparinmimicking" compounds, but there was no effect in response to various glycosaminoglycans (ie, heparin, heparan sulfate, dermatan sulfate, or hyaluronic acid), anionic molecules (ie, suramin or dextran sulfate), adhesive grycoproteins (ie, laminin or fibronectin), and growth factors (ie, bFGF or TGF-/3). Surprisingly, binding of RG-13577 to SMCs was reduced by 65% in the presence of a 20 -fold excess (molar ratio) of recombinant apoE. This result, together with recent observations on the antiproliferative effect of apoE, 31 suggests that RG-13577 and related compounds may inhibit SMC proliferation via interaction with the LDL receptor-related protein or another member of the LDL receptor gene family. 32 This possibility is under investigation. Specific binding of RG-13577 was reduced by about 50% in the presence of 1 mol/L NaCl, suggesting involvement of an electrostatic interaction between the polyanionic polymer and polybasic proteins. 19 Cross-linking experiments revealed the presence of a high-molecular-weight (=280 kD) cell surface receptor that was cross-linked to 125 I-RG-13577 in the absence but not the presence of excess unlabeled RG-13577. Scatchard analysis revealed a relatively low-affinity (Kd=3xl0-* mol/L) binding of about lxlO 7 RG-13577 molecules per cell. Although the natural ligand that binds to these receptor sites is not yet identified, it is conceivable that the antiproliferative activity of compound RG-13577 is initiated by binding to these specific cell surface receptors. Receptor activation may then transduce an antiproliferative signal through modulation of tyrosine phosphorylation, 33 kinase C activity, and other cell cycle-related activities. This implied that heparin and other polysulfated molecules exert their antiproliferative activity via a different pathway, since they failed to compete with RG-13577 receptor binding. Alternatively, the "heparin-mimicking" compounds may exert an antiproliferative effect by interacting with and blocking the activity of various growth-promoting factors, such as thrombin, PDGF, and bFGF, as has been observed with suramin.
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- 34 Direct interaction between compound RG-13577 and bFGF is suggested by the ability of the former to release bFGF that is bound to the ECM or heparinSepharose. 17 Approximately 60% of the bound 125 I-bFGF was released from the ECM or heparin-Sepharose by 10 jAg/mL RG-13577 compared with a similar release by 1 /xg/mL heparin, suggesting a 10-fold difference in binding affinities. RG-13577 binding to bFGF may inhibit subsequent binding of bFGF to low-and high-affinity receptor sites on the surface of SMCs, leading to inhibition of bFGF mitogenic activity, as observed in the present study. Likewise, the ability of RG-13577 to inhibit autocrine proliferation and transformation of bFGF-transfected 3T3 fibroblasts may be due to its direct interaction with bFGF. 17 Binding of bFGF to heparan sulfate on cell surfaces is involved in subsequent high-affinity receptor binding and mitogenic response. 14 - 25 Receptor binding and activation are restored upon the addition of heparin to heparan sulfate-deficient cells.
-
25
- 35 This restoration was inhibited by ATA and RG-13577 (M.B. et al, unpublished data, 1994), providing another possible mechanism for the antiproliferative effect of RG-13577 on cells that are exposed to bFGF and possibly other members (eg, vascular endothelial growth factor) of the heparin-binding family of growth factors. 36 Unlike the effect on bFGF binding and mitogenic activity, inhibition of thrombininduced proliferation of SMCs did not correlate with the effect of RG-13577 on thrombin binding to cell surface receptor sites. On the contrary, a significantly higher binding of thrombin was obtained, regardless of whether the SMCs were incubated with l2 *I-thrombin in the presence of compound RG-13577 or after preincubation of the cells with RG-13577 and removal of the unbound compound (not shown). A better understanding of the inhibitory effect exerted by "heparin-mimicking" compounds on thrombin-induced SMC proliferation is needed in view of the increasing significance attributed to thrombin in the initiation and progression of atherosclerosis.
Both heparin and RG-13577 are polyanionic and pluripotent, exhibiting a wide range of activities. While their chemical compositions and possibly modes of action are different, their supramolecular conformation and biological effects may be similar. Using a series of 14 different but closely related "heparin-mimicking" compounds, we are currently performing structurefunction analyses to determine the specific requirements for inhibition of SMC proliferation. Two correctly spaced chemical components, a substituted aromatic ring system and a negatively charged acidic residue, were needed for this activity. Our preliminary results emphasize the feasibility of designing "heparinmimicking" compounds that will elicit specific effects, such as inhibition of SMC proliferation, release of ECM-bound bFGF, and inhibition of heparanase activity. 37 The newly designed compounds may have potential clinical applications in the treatment of disorders involving abnormal SMC proliferation, neovascularization, and cell invasion.
